New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
07:06 EDTFATEFate Therapeutics announces issuance of U.S. patent for Stem Cell Cultures
Fate Therapeutics announced that the U.S. Patent and Trademark Office has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase, or ROCK, that are crucial to the therapeutic application of human induced pluripotent stem cells, or hiPSCs. Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute to the patent in all commercial fields.
News For FATE From The Last 14 Days
Check below for free stories on FATE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
16:24 EDTFATEFate Therapeutics announces FDA clearance of IND for PROHEMA
Fate Therapeutics announced that the FDA has cleared its Investigational New Drug Application, or IND, for the clinical development of PROHEMA in pediatric patients undergoing hematopoietic stem cell transplantation for the treatment of inherited metabolic disorders, or IMDs. The FDA's clearance of the IND allows the company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The company plans to initiate enrollment of the PROVIDE trial in pediatric patients with IMDs in Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use